Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Current Liabilities for 7 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 50.9% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, up 50.9% year-over-year, with the annual reading at $44.0 million for FY2025, 50.9% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $44.0 million at 4D Molecular Therapeutics, up from $37.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $44.0 million in Q4 2025, with the low at $9.9 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $20.3 million, with a median of $16.4 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities dropped 13.11% in 2022, then soared 78.72% in 2025.
  • Over 5 years, Total Current Liabilities stood at $16.3 million in 2021, then dropped by 3.72% to $15.7 million in 2022, then rose by 20.47% to $19.0 million in 2023, then skyrocketed by 53.81% to $29.1 million in 2024, then skyrocketed by 50.9% to $44.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $44.0 million, $37.1 million, and $34.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.